Loading clinical trials...
Loading clinical trials...
A Study to Evaluate the Efficacy and Safety of Genormab Injection in Chinese Patients With Recurrent or Refractory B-cell Non-Hodgkin's Lymphoma (B-NHL)
Conditions
Interventions
GB226
Locations
1
China
Cancer Hospital Chinese Academy of Medical Sciences
Beijing, Beijing Municipality, China
Start Date
October 15, 2018
Primary Completion Date
September 1, 2021
Completion Date
December 30, 2022
Last Updated
March 3, 2021
NCT07334574
NCT03985189
NCT00457782
NCT05322330
NCT04746131
NCT05453669
Lead Sponsor
Genor Biopharma Co., Ltd.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions